Anika Therapeutics Inc logo

ANIKAnika Therapeutics Inc

NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

$21.20

+$0.09 (+0.43%)

Anika Therapeutics Inc (ANIK) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Cheryl Renee Blanchard Ph.D., based in 32 Wiggins Avenue, Bedford, MA, United States, 01730, with about 288 employees. Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

Latest reported ANIK revenue for 2025-09-30 was $27.8M. Net income was -$2.3M. Revenue was down 1.4% from 2025-06-30 to 2025-09-30. ANIK currently screens at market cap $161.3M.

Use this ANIK page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the ANIK quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the ANIK SEC filings page. Lician reads the product cache first so this HTML stays unique to Anika Therapeutics Inc even when a live quote feed is slow.

About Anika Therapeutics Inc

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products include Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide short-and long-term pain relief. The company's joint preservation and restoration product family comprises orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants to treat upper and lower extremity orthopedic conditions. In addition, the company offers non-orthopedic products comprising HA-based products for Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier for use after abdominal-pelvic surgeries; and Hyalomatrix for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.

ANIK Key Statistics

Market Cap

$161.34M

Volume

73,458

Previous Close

$21.34

Day Range

$21.35$21.92

00

EPS

-$3.83

Revenue

$119.91M

Net Income

-$56.38M

Gross Profit

$0.00

Free Cash Flow

$0.00

Revenue Growth

-0.7%

Profit Margin

-47.0%

Employees

288

ANIK Financials

Annual income statement in USD. Latest reported periods first.

ANIK annual income statement across FY2024, FY2023, FY2022, FY2021
LineFY2024FY2023FY2022FY2021
Revenue$119.91M$120.79M$113.83M$147.79M
Cost of Revenue$0.00$0.00$0.00$0.00
Gross Profit$0.00$0.00$0.00$0.00
Operating Income$0.00$0.00$0.00$0.00
Net Income-$56.38M-$82.67M-$14.86M$4.13M
EPS (Diluted)-$3.83-$5.64-$1.02$0.28

Total Assets

$202.74M

Total Debt

$0.00

Shareholders' Equity

$0.00

Cash & Equivalents

$55.63M

Operating Cash Flow

$5.40M

Free Cash Flow

$0.00

Anika Therapeutics Inc Company Information

President, CEO & Director
Cheryl Renee Blanchard Ph.D.
Headquarters
32 Wiggins Avenue, Bedford, MA, United States, 01730
Phone
781 457 9000
IPO / Founded
1993-04-29
Industry
Drug Manufacturers - Specialty & Generic
Data Updated:

Upcoming Events for ANIK